debt_leverage_profile
Net debt ~$700M; high leverage for a biotech with volatile revenue; 20% rate rise adds ~$140M annual interest burden, threatening liquidity runway.
Inferred
Agent_Inference
interest_rate_sensitivity
Floating-rate exposure on credit facilities means 20% rate increase (~100-150bps) adds $30-50M incremental annual interest cost, pressuring cash burn.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Serum Institute of India (bulk antigen manufacturing) and Czech Republic fill-finish facilities are top two geopolitical chokepoints.
Inferred
Agent_Inference
international_expansion_readiness
Material exposure to EUR (EU procurement), JPY (Japan partnership via Takeda), and INR (SIIPL manufacturing); currency devaluation could reduce effective royalty and supply revenue 10-20%.
Inferred
Agent_Inference
geographic_footprint
Revenue concentrated in EU, Japan, and select low-income markets; EUR and JPY weakness vs USD directly compresses reported revenue and margins.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Serum Institute of India supplies bulk nanoparticle antigen; single-source relationship represents non-substitutable input, likely >30% of COGS — high vendor lock risk.
Inferred
Agent_Inference
business_model_type_primary
Biologics manufacturer/licensor; cloud dependency is moderate but not mission-critical; 30-day cloud termination would disrupt R&D and ERP, not manufacturing.
Inferred
Agent_Inference
business_model_type_secondary
Secondary model is licensing/royalties (e.g., Sanofi deal); cloud disruption would impair data analytics and regulatory submissions but not license revenue directly.
Inferred
Agent_Inference
switching_cost_profile
Limited API coupling risk; primary technology is proprietary nanoparticle vaccine platform, not software APIs; switching cost for partners is scientific/regulatory, not technical.
Inferred
Agent_Inference
howey_test_risk_index
Primary revenue is vaccine product sales and licensing; does not resemble an investment contract — Howey Test risk is negligible/not applicable.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Handles clinical trial participant data across EU and US; GDPR exposure is moderate; CCPA exposure is low given B2G/B2B model; compliance infrastructure appears adequate.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; operates in competitive vaccine market with Pfizer, Moderna, J&J; no dominant market share; government procurement is competitive tender-based.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional (government procurement contracts); multi-year supply agreements provide partial predictability but ~80%+ revenue is non-recurring contract-by-contract.
Inferred
Agent_Inference
monetization_vector
Primary monetization via bulk vaccine product sales to governments/COVAX; secondary via licensing royalties from Sanofi partnership (~$1.2B deal value).
Inferred
Agent_Inference
pricing_architecture
Pricing set by government negotiation and COVAX tiered structures; limited pricing power; cost-plus dynamics dominate; stress scenario shows margin compression if raw material costs rise.
Inferred
Agent_Inference
pricing_power_rating
Low-to-moderate; government buyers have monopsony leverage; differentiation via protein-subunit platform provides modest premium over legacy flu vaccines but not COVID mRNA leaders.
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margin 40-55% at scale; currently depressed (~20-30%) due to low COVID vaccine volumes and high fixed manufacturing overhead utilization.
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider problem; vaccines are physical goods with direct procurement. Churn risk is contract non-renewal by governments if competing vaccines dominate — high cyclical vulnerability.
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is largely sublinear to headcount; manufacturing scale-up requires capital not proportional headcount; R&D headcount grows modestly with pipeline expansion.
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is capital-intensive (bioreactor capacity) but not headcount-linear; incremental doses have declining per-unit COGS at scale — semi-scalable model.
Inferred
Agent_Inference
franchise_compliance_risk
Not a franchise model; null.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC is effectively zero (government RFP-driven); unit economics depend on COGS reduction via manufacturing efficiency; gross profit per dose must exceed ~$3-5.
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; vaccine adoption is driven by public health mandates and efficacy data, not user-base size — network effect durability is negligible.
Inferred
Agent_Inference
asset_efficiency_ratio
37.6% Return on Assets (Outstanding)
High
SEC-XBRL
recession_resistance_tier
Moderate-to-high recession resistance for pandemic/government-mandated vaccines; discretionary travel vaccines more vulnerable; revenue tied to government budgets, not consumer spending.
Inferred
Agent_Inference
customer_segment_primary
Sovereign governments and supranational bodies (COVAX, CEPI) represent primary customer segment; high concentration risk — top 3 governments likely >60% of revenue.
Inferred
Agent_Inference
customer_segment_secondary
Secondary segment: commercial pharmacy channels and private healthcare payers in developed markets (US, EU); growing but currently <20% of total revenue.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capex shifting from COVID surge capacity (legacy) toward combination flu-COVID pipeline and next-gen manufacturing; reallocation underway but legacy facility costs remain a drag.
Inferred
Agent_Inference
sec_cik
0001000694
High
SEC-EDGAR
ticker
NVAX
High
SEC-EDGAR